On September 30, 2009
AstraZeneca on Suicide Mission in Drug Pricing Litigation
AstraZeneca appears to be on a suicide mission in its average wholesale price litigation. Yesterday we saw how it lost a $13 million appeal of a Massachusetts federal court ruling that found AZ illegally marketed the spread between the actual price of Zoladex and its Medicare reimbursed rate. That turns out to be the tip of AZ’s iceberg.
0 Comments